The ASCENT Trial and Its Impact on Breast Cancer Treatment

The ASCENT trial established sacituzumab govitecan as a transformative treatment for metastatic triple-negative breast cancer, a subtype that had long been one of the hardest to treat. In its final analysis, patients receiving sacituzumab govitecan lived a median of about 12 months compared with roughly 7 months on standard chemotherapy, and disease progression was held off nearly three times longer. Those results reshaped clinical guidelines and opened the door to an entirely new class of targeted therapy for breast cancer.

What the Trial Tested and Found

Triple-negative breast cancer accounts for roughly 10 to 15 percent of all breast cancers and lacks the three most common receptor targets, meaning many standard targeted therapies do not work against it. Patients whose disease has spread and who have already been through multiple rounds of treatment historically faced limited options. The ASCENT trial enrolled 529 patients with metastatic triple-negative breast cancer who had already received at least two prior therapies. Half were randomized to receive sacituzumab govitecan, and half received a physician’s choice of standard single-agent chemotherapy.

The initial publication reported a median progression-free survival of 5.6 months with sacituzumab govitecan versus 1.7 months with chemotherapy, with a hazard ratio of 0.41, meaning the drug cut the risk of disease progression or death by about 59 percent.¹ The final analysis, with longer follow-up and more data, confirmed the benefit: median progression-free survival was 4.8 versus 1.7 months, and median overall survival was 11.8 versus 6.9 months, with sacituzumab govitecan cutting the risk of death by about half.² For a cancer subtype where prior later-line therapies had produced response rates in the single digits, these were striking numbers.

How the Drug Works

Sacituzumab govitecan belongs to a class called antibody-drug conjugates. The concept is straightforward: attach a potent cancer-killing chemical to an antibody that knows how to find tumor cells, so the toxic payload gets delivered directly to the cancer instead of flooding the whole body. In this case, the antibody homes in on a protein called Trop-2, which sits on the surface of many solid tumors at much higher levels than on normal tissue. The payload is SN-38, a potent chemotherapy agent that damages DNA and stops cancer cells from dividing.

What makes sacituzumab govitecan distinctive is its engineering. Each antibody molecule carries roughly eight drug molecules, a higher ratio than many other antibody-drug conjugates. The linker connecting the drug to the antibody is designed to be stable in the bloodstream but to break apart once inside the acidic environment of the tumor, releasing SN-38 where it is needed.³ Preclinical work showed the drug could deliver over 100 times more SN-38 to a tumor than irinotecan, the traditional prodrug form of SN-38. It also delivers SN-38 in its most active chemical form, which may explain why severe diarrhea is less common than with irinotecan.⁴

There is also a so-called bystander effect: once SN-38 is released inside a Trop-2-positive cell, free drug can leak into the surrounding tumor environment and kill nearby cancer cells that may not express Trop-2 at all.³ That bystander killing adds a layer of activity that purely targeted drugs miss.

Does Trop-2 Level Predict Who Benefits

Because sacituzumab govitecan targets Trop-2, researchers naturally wondered whether patients with higher Trop-2 expression on their tumors would benefit more. The biomarker analysis from ASCENT sorted patients into high, medium, and low Trop-2 groups. In the high-expression group, sacituzumab govitecan produced a median progression-free survival of 6.9 months compared with 2.5 months on chemotherapy, and overall survival reached about 14 months versus roughly 7 months. Objective response rates hit 44 percent in the high-expression group versus just 1 percent on chemotherapy.⁵

Here is what makes it interesting: even patients with low Trop-2 expression still did better on sacituzumab govitecan than on chemotherapy. Their progression-free survival was 2.7 versus 1.6 months, and response rates were 22 percent versus 6 percent.⁵ The drug worked across the board, though the magnitude of benefit tracked with Trop-2 levels. This is one reason sacituzumab govitecan was approved without requiring a Trop-2 test as a prerequisite for prescribing, though ongoing work is exploring whether standardized Trop-2 testing could sharpen treatment decisions.⁶

Side Effects and the Role of UGT1A1 Genetics

Sacituzumab govitecan is effective, but it comes with a meaningful side-effect profile. In the ASCENT trial, the most common severe side effects were neutropenia (low white blood cell counts), diarrhea, anemia, and nausea. Real-world data from outside the controlled trial setting showed that about half of patients experienced grade 3 or higher adverse events, with neutropenia affecting roughly a third. About half of patients required dose reductions, and around 13 percent stopped treatment because of side effects.⁷

One factor that significantly influences how toxic the drug is for individual patients is a genetic variation in the UGT1A1 enzyme. This enzyme is responsible for metabolizing SN-38 in the body. People who carry two copies of a variant called *28 (homozygous *28/*28) process SN-38 more slowly, leading to higher drug levels in the blood. In the ASCENT trial’s safety analysis, patients with the *28 homozygous genotype had a substantially higher rate of severe febrile neutropenia, at 18 percent, compared with 5 percent in those carrying one variant copy and 3 percent in those with the normal genotype. Severe anemia and diarrhea were also more common in this group.⁸

A meta-analysis pooling data across multiple studies found that *28 homozygous patients had about a sevenfold increased risk of severe toxicity overall.⁹ A separate analysis reached similar conclusions and recommended pre-treatment UGT1A1 genotyping to help clinicians anticipate and manage toxicity.¹⁰ This does not mean *28 homozygous patients should not receive the drug, but it does mean they may need closer monitoring or proactive dose adjustments. Efforts are also underway to prevent the two most troublesome side effects. A phase 2 trial tested prophylactic granulocyte colony-stimulating factor and loperamide in patients starting sacituzumab govitecan and significantly reduced the rate of severe neutropenia to 16 percent during the first two treatment cycles.¹¹

What Happened to Quality of Life

A fair question for any cancer drug is whether the extra months of survival come at the cost of feeling miserable on treatment. The quality-of-life analysis from ASCENT paints a nuanced picture. Patients on sacituzumab govitecan had better overall quality of life, better physical functioning, and less fatigue and pain compared with those on standard chemotherapy. The time before physical functioning significantly worsened was about 22 weeks on sacituzumab govitecan versus 12 weeks on chemotherapy, and for pain it was about 22 weeks versus 10 weeks.¹²

The trade-off was gastrointestinal: patients on sacituzumab govitecan had worse nausea, vomiting, and diarrhea than those on standard chemotherapy.¹³ So the drug was not side-effect-free by any stretch, but for most patients the gains in pain control, energy, and physical ability outweighed the increase in gut-related symptoms. That matters for how patients and their oncologists weigh decisions, especially in a setting where the alternative chemotherapy options also carry their own burdens.

How Tumors Develop Resistance

Not everyone responds to sacituzumab govitecan, and among those who do respond, the cancer eventually finds a way around the drug. Researchers have identified two parallel routes of resistance, both emerging from the same patient’s cancer but in genetically distinct branches. One path involves mutations in TOP1, the enzyme that SN-38 targets. A well-known mutation called E418K alters the enzyme in a way that makes it less vulnerable to SN-38. In one case, a second hit, a frameshift mutation in TOP1, appeared to stack on top of E418K to further strengthen resistance.¹⁴

The second path hits the other end of the drug: the Trop-2 target itself. A previously undescribed mutation in the TROP2 gene, T256R, prevented the Trop-2 protein from properly reaching the cell surface. If Trop-2 is not on the outside of the cell, the antibody cannot bind, and the drug cannot deliver its payload. Strikingly, these two resistance mechanisms evolved in separate tumor branches within the same patient, with the TOP1 mutations dominating in abdominal metastases and the TROP2 mutation dominating in chest wall and lung metastases.¹⁴ This tells us that cancers can simultaneously attack both halves of an antibody-drug conjugate, the antibody’s target and the chemotherapy payload, which has implications for how future drugs in this class are designed.

Expanding Beyond Triple-Negative Breast Cancer

ASCENT addressed triple-negative disease, but Trop-2 is also expressed on hormone receptor-positive, HER2-negative breast cancers, the most common subtype. The TROPiCS-02 trial tested sacituzumab govitecan in these patients after they had exhausted endocrine therapy and at least two prior chemotherapy regimens. The primary endpoint was met: progression-free survival improved from 4.0 to 5.5 months, a 34 percent reduction in the risk of progression or death.¹⁵ Final overall survival data showed a median of 14.4 months versus 11.2 months, a roughly 3-month improvement that held across Trop-2 expression levels.¹⁶

The survival benefit was smaller than in ASCENT, which makes sense because hormone receptor-positive cancers generally grow more slowly and have more treatment options available. But for heavily pretreated patients running out of lines, those extra months were clinically meaningful. This second approval broadened sacituzumab govitecan’s impact considerably, making it relevant to a much larger share of metastatic breast cancer patients. Clinical guidelines now recommend sacituzumab govitecan for triple-negative patients who have received at least two prior therapies.¹⁷

Combining With Immunotherapy

One of the most important developments building on ASCENT is the move to combine sacituzumab govitecan with immunotherapy as a first-line treatment, rather than saving it for later lines. The ASCENT-04 trial tested sacituzumab govitecan plus pembrolizumab, an immune checkpoint inhibitor, versus chemotherapy plus pembrolizumab as upfront treatment in patients with PD-L1-positive metastatic triple-negative breast cancer. The results were impressive: median progression-free survival was 11.2 months with the sacituzumab govitecan combination versus 7.8 months with standard chemotherapy plus pembrolizumab. Sixty percent of patients responded to the sacituzumab govitecan combination, and those responses lasted a median of 16.5 months compared with 9.2 months in the chemotherapy arm.¹⁸

Notably, the rates of severe side effects were similar between the two arms, at about 70 to 71 percent. But patients on the sacituzumab govitecan combination were less likely to discontinue treatment due to side effects: 12 percent versus 31 percent. That is a remarkable gap suggesting the combination is not only more effective but in some ways more tolerable than standard chemo-immunotherapy, at least in terms of keeping patients on treatment. If these results hold up in overall survival data, this combination could replace chemotherapy as the backbone of first-line treatment for PD-L1-positive triple-negative breast cancer.

Sequencing With Other Antibody-Drug Conjugates

Sacituzumab govitecan is not the only antibody-drug conjugate making waves in breast cancer. Trastuzumab deruxtecan, which targets HER2, has its own impressive track record, including in HER2-low tumors that overlap with sacituzumab govitecan’s patient population. A practical question clinicians face is which drug to give first and whether the second one still works.

Early real-world data suggest that whichever antibody-drug conjugate is given first tends to work better than the one that follows. In one multicenter study of patients with HER2-low, hormone receptor-positive metastatic breast cancer who received sacituzumab govitecan before trastuzumab deruxtecan, the response rate was 77 percent for the first drug and 35 percent for the second, with a noticeable drop in time on treatment.¹⁹ A separate analysis found similar patterns regardless of which antibody-drug conjugate came first: the median progression-free survival for the first was roughly 5.5 months and dropped to about 3.1 to 3.4 months for the second.²⁰ The second drug still offered benefit, and patients with brain metastases showed stable disease, but there appears to be some cross-resistance. The optimal sequencing strategy remains an active area of research.

Patients With Brain Metastases

The original ASCENT trial excluded patients with active, untreated brain metastases, leaving a gap in the evidence for a group that desperately needs effective options. Triple-negative breast cancer has a particular tendency to spread to the brain, and outcomes for those patients are historically poor. A real-world study from Institut Curie in France examined sacituzumab govitecan specifically in patients with brain metastases. Median progression-free survival was 3.7 months and overall survival was 6.7 months, with some patients achieving intracranial tumor responses.²¹ Those numbers are modest compared with the overall ASCENT population, but any sign of intracranial activity from an antibody-drug conjugate is encouraging. Large antibody-based molecules were long assumed to have difficulty crossing the blood-brain barrier, so evidence of brain responses has drawn attention.

Real-World Outcomes Versus the Clinical Trial

Clinical trials enroll patients who meet strict criteria: good organ function, certain performance status, limited prior treatments. Real-world patients are often sicker, older, or more heavily pretreated. So how does sacituzumab govitecan perform outside the controlled environment? A large real-world study found a median overall survival of about 9.6 months and a median progression-free survival of 4.8 months, with an objective response rate of about 28 percent.⁷ The progression-free survival is essentially identical to the final ASCENT analysis, and overall survival is somewhat shorter, which is expected given the broader patient population. The response rate was lower than the trial’s, but still meaningful for this disease setting. The toxicity profile was also consistent, with about half of patients needing dose reductions.

Cost and Access Challenges

Sacituzumab govitecan is expensive, and cost-effectiveness analyses from several countries have raised concerns. In China, where multiple analyses have been conducted, the incremental cost per quality-adjusted life year gained ranged from roughly $212,000 to over $323,000 depending on the breast cancer subtype and the model used.²²²³ At standard willingness-to-pay thresholds used by health economists in those analyses, the probability of the drug being cost-effective was essentially zero. One model estimated that a price reduction of about 83 percent would be needed for the drug to clear the cost-effectiveness bar.²²

These are Chinese analyses using Chinese willingness-to-pay thresholds, and cost-effectiveness calculations look different in countries with higher per-capita income or different insurance structures. In the United States, where the drug has been commercially available since 2020, access depends heavily on insurance coverage and specialty pharmacy pathways. The gap between strong clinical evidence and the question of who can actually afford the treatment is a tension point that runs through modern oncology, and sacituzumab govitecan is no exception. A trial-based cost-effectiveness analysis found similar conclusions, noting that monthly cost would need to drop substantially for the drug to have even a 50 percent chance of being preferred over standard chemotherapy on economic grounds.²⁴

Moving Into Earlier-Stage Disease

ASCENT, TROPiCS-02, and ASCENT-04 all studied patients with metastatic disease, where the cancer has already spread and the goal is to extend life rather than cure it. The natural question is whether sacituzumab govitecan could help earlier, potentially before or after surgery when there is still a chance of cure. The NeoSTAR trial began exploring sacituzumab govitecan as a neoadjuvant treatment, meaning it is given before surgery to shrink the tumor.²⁵ Moving effective metastatic drugs into earlier disease stages is a common strategy in oncology, and results from these trials will determine whether sacituzumab govitecan can help prevent recurrence and potentially cure more patients, rather than just being reserved for when other options have failed.